News

IMI-money for intelli-research
Enlarge image

FundingEUUKSwitzerland

IMI-money for intelli-research

06.12.2012 - The Innovative Medicines Initiative funds seven new projects with a total of €237m. The main focus is on drug development and data integration.

The exciting field of stem cell research and the seemingly insurmountable ranges of biodata are undergoing in-depth analyses over the next few years. The unifying context behind these projects is the mission to improve drug development. As announced on 5 December, the Innovative Medicines Alliance (IMI) will spend in total more than €237m on research topics ranging from stem cells (STEMBANCC), data integration (EMIF and eTRIKS) and ‚green’ drug development (CHEM21) to drug-target-interaction (K4DD), drug uptake into (ORBITO) and drug distribution within (COMPACT) the body.

Within STEMBANCC ten pharmaceutical companies and 23 academic institutions from 11 countries will develop 1,500 human induced pluripotent stem cell lines from about 500 patients to study diseases and test drugs for safety and efficacy. Swiss pharma Roche initiated the project, which will be coordinated by the University of Oxford (UK). Using cells isolated from patients, the scientists hope to identify the genes and mechanisms that play a role in diseases of the nervous system such as peripheral pain, migraine, autism, schizophrenia, bipolar disorders, dementiae and diabetes. Taken together, IMI now finances 37 projects with a volume of almost €800m.

It was just in June this year, that the last current IMI projects were presented. The €215m they received is only 91% of the sum the new projects of the 4th wave will get. The IMI, a joint venture of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) is Europe’s biggest public-private partnership to accelerate the development of better drugs. Currently, applicants can bid for the 8th call „Combating Antibiotic Resistance“. The calls five to seven have already been closed for submission of Expressions of Interest (EoI) and are in different stages of processing.

© eurobiotechnews.eu/ml

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.54 EUR103.6%

FLOP

  • THROMBOGENICS (B)8.51 EUR-52.2%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 11.07.2014